Skip to main content
. Author manuscript; available in PMC: 2009 Jun 18.
Published in final edited form as: J Cardiovasc Pharmacol. 2008 May;51(5):437–442. doi: 10.1097/FJC.0b013e318168d120

Table 2.

Plasma parameters and renal function in response to the treatment

Vehicle CAP CAPZ + CAP CAPZ
Hct, % 44.8±0.9 43.9±0.7 45.0±0.7 45.0±0.8
TP, mg·ml−1 58.1±5.5 59.9±4.7 53.2±5.8 63.3±0.9
[Na+]P, mmol·L−1 134.7±2.1 137.6±4.4 134.9±1.7 134.8±1.8
[Cr]P, mg/·dL−1 0.68±0.08 0.59±0.03 0.66±0.09 0.57±0.04
[Li+]P, mmol·L−1 0.24±0.04 0.26±0.01 0.24±0.02 0.25±0.02
FELi, % 40±11 34±8 32±6 24±1
FENa, % 1.6±0.3 2.1±0.4 1.9±0.4 1.2±0.1
APR, ml·min−1 0.5±0.1 1.0±0.3 0.6±0.1 0.7±0.1
FPR, % 60±11 66±8 68±6 76±1
FDRNa, % 95±1 94±1 94±1 95±1
FDRH2O, % 94±1.1 94±0.3 93±0.4 93±0.5

Values are expressed as mean ± SE, n= 5–6 rats. ++ p ≤ 0.01 vs Vehicle, CAPZ + CAP and CAPZ groups. Hct, hematocrit; TP, total protein; [Na+]P, plasma sodium concentration; [Cr]P, plasma creatinine concentration; [Li+]P, plasma lithium concentration; GFR, glomerular filtration rate; FELi, fractional excretion of lithium; FENa, fractional excretion of sodium; APR, absolute proximal reabsorption; FPR, fractional proximal reabsorption; FDRNa, fractional distal sodium reabsorption; FDRH2O, fractional distal water reabsorption.